|Condition or Disease||Intervention / Treatment||Phase||Sponsor||Status|
|Non Infectious Uveitis|| DE-109 Sirolimus|
This study will assess the efficacy and safety of sirolimus DE-109 every 2 months in subjects with active, non-infectious uveitis of the posterior segment of the eye (NIU-PS).
Intervetion/Treatment Arms: Subjects are randomly assigned to one of these:
There is a 6-month, single-arm, open-label period after completion of the 6-month double-masked, controlled period. This allows the evaluation of the efficacy and safety of intravitreal injection of DE-109 440 µg every 2 months for longer duration than appropriate for a placebo or sham control.
Beachwood Office: Dianne Himmelman 216-831-5700 • email@example.com
To Learn More: Go to https://clinicaltrials.gov/ct2/show/NCT03711929